Analysis of the degradation function of Mdm2

Cell Growth and Differentiation

Volumn 10, Issue 2, 1999, Pages 87-92

  Kubbutat, Michael H G ^a   Ludwig, Robert L ^a   Levine, Arnold J ^b   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL DEATH; CELL PROLIFERATION; DNA DAMAGE; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TARGET CELL; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; BLOTTING, WESTERN; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL LINE; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MICE; MUTAGENESIS; NUCLEAR PROTEINS; POINT MUTATION; PRECIPITIN TESTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032963156     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
2. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E., Smith-Sørensen, B., Montesano, R., and Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22: 3551-3555, 1994.
3. Kubbutat, M. H. G., and Vousden, K. H. Keeping an old friend under control: regulation of p53 stability. Mol. Med. Today, 4: 250-256, 1998.
4. Kubbutat, M. H. G., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature (Lond.), 387: 299-303, 1997.
5. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
6. Böttger, A., Böttger, V., Sparks, A., Liu, W-L., Howard, S. F., and Lane, D. P. Design of a synthetic Mdm-2 binding mini-protein that activates the p53 response in vivo. Curr. Biol., 7: 860-869, 1997.
7. Honda, R., Tanaka, H., and Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420: 25-27, 1997.
8. Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., and Levine, A. J. Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 17: 554-564, 1998.
9. Barak, Y., Juven, T., Haffner, R., and Oren, M. mdm-2 expression is induced by wild type p53 activity. EMBO J., 12: 461-468, 1993.
10. Momand, J., Zambetti, G. P., George, D. L., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
11. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (Lond.), 362: 857-860, 1993.
12. Wu, X. W., Bayle, J. H., Olson, D., and Levine, A. J. The p53 mdm-2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132, 1993.
13. Montes de Oca Luna, R., Wagner, D. S., and Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (Lond.), 378: 203-206, 1995.
14. Jones, S. N., Roe, A. E., Donehower, L. A., and Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (Lond.), 378: 206-208, 1995.
15. Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., and Finlay, C. A. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev., 11: 714-725, 1997.
16. Brown, L. R., Thomas, C. A., and Deb, S. P. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J., 17: 2513-2525, 1998.
17. Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E., and Lunec, J. Alternatively spliced mdm2 transcripts with bss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med., 2: 912-917, 1996.
18. Leveillard, T., and Wasylyk, B. The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. J. Biol. Chem., 272: 30651-30661, 1997.
19. Thut, C. J., Goodrich, J. A., and Tjian, R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev., 11: 1974-1986, 1997.
20. Xiao, Z-X., Chen, J., Levine, A., Modjtahedi, N., Xing, J., Sellers, W. R., and Livingston, D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature (Lond.), 375: 694-697, 1995.
21. Martin, K., Trouche, D., Hagemeier, C., Sørensen, T. S., La Thangue, N. B., and Kouzarides, T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature (Lond.), 375: 691-694, 1995.
22. Kubbutat, M. H. G., Ludwig, R. L., Ashcroft, M., and Vousden, K. H. Regulation of Mdm2 directed degradation by the C-terminus of p53. Mol. Cell. Biol., 18: 5690-5698, 1998.
23. Chen, J., Lin, J., and Levine, A. J. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med., 1: 142-152, 1995.
24. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
25. Frische, M., Haessler, C., and Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8: 307-318, 1993.
26. Chang, Y.-C., Lee, Y.-S., Tejima, T., Tanaka, K., Omura, S., Heintz, N. H., Mitsui, Y., and Magae, J. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9: 79-84, 1998.
27. Nuber, U., Schwarz, S. E., and Scheffner, M. The ubiqutin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. Eur. J. Biochem., 254: 643-649, 1998.
28. Elenbaas, B., Dobbelstein, M., Roth, J., Shenk, T., and Levine, A. J. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med., 2: 439-451, 1996.
29. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J., 17: 5001-5014, 1998.
30. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
31. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
32. Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75: 495-505, 1993.
33. Haupt, Y., Barak, Y., and Oren, M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J., 75: 1596-1606, 1996.
34. Marston, N. J., Crook, T., and Vousden, K. H. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild-type transformation suppressor function. Oncogene, 9: 2707-2716, 1994.
35. Helin, K., and Harlow, E. Heterodimerization of the transcription factors E2F-1 and DP-1 is required for binding to the adenovirus E4 (ORF6/7) protein. J. Virol., 68: 5027-5035, 1994.
36. Helin, K., Wu, C., Fottaey, A., Lees, J., Dynlacht, B., Ngwu, C., and Harlow, E. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative transactivation. Genes Dev., 7: 1850-1861, 1993.
37. Qin, X.-Q., Chittenden, T., Livingston, D. M., and Kaelin, W. G., Jr. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev., 6: 953-964, 1992.
38. Marston, N. J., Jenkins, J. R., and Vousden, K. H. Oligomerisation of full-length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene, 10: 1709-1715, 1995.